BETA Technologies launches IPO of 25 million shares priced $27-$33
James C. Clemmer, President and CEO of Angiodynamics Inc (NASDAQ:ANGO), acquired 10,000 shares of common stock on October 9, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The medical device company, currently valued at $459 million, has seen its stock surge 81% over the past year according to InvestingPro data.
The shares were purchased at a weighted average price of $11.15, in multiple transactions at prices ranging from $11.10 to $11.17, resulting in a total transaction value of $111,500. Following the transaction, Clemmer directly owns 882,529 shares of Angiodynamics. According to InvestingPro analysis, the stock is trading near its Fair Value, with analyst targets ranging from $16 to $24, suggesting potential upside. Get access to the comprehensive Pro Research Report and 7 additional InvestingPro Tips for ANGO to make more informed investment decisions.
In other recent news, AngioDynamics reported its fiscal first quarter 2026 earnings, surpassing both revenue and earnings per share (EPS) forecasts. The company achieved a revenue of $75.7 million, exceeding the forecasted $72.7 million, while EPS came in at -$0.10, beating the expected -$0.12. This strong performance led Canaccord Genuity to raise its price target for AngioDynamics to $18.00 from $17.00, maintaining a Buy rating. The firm highlighted the robust performance of all three Med-Tech businesses and noted the company’s progress toward positive cash flow for the fiscal year 2026. Additionally, H.C. Wainwright reiterated a Buy rating with a price target of $16.00, following the company’s financial results. AngioDynamics reported a 12.2% year-over-year growth in net sales for the quarter ending August 31, 2025. The Med Tech segment saw a 26.1% increase in sales, while the Med Device segment experienced a 2.3% growth. These recent developments reflect a positive outlook from analysts regarding AngioDynamics’ financial health and market performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.